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Objective:Wesought to characterize the treatment, aswell as define the long-termoutcomes, of
patients with recurrent neuroendocrine liver metastasis (NELM).
Methods: Between 1990 and 2014, 322 patients undergoing curative intent liver surgery for
NELM were identified from a multi-institutional database. Recurrences were classified as
intrahepatic, extrahepatic, and both intra- and extra-hepatic.
Results: Overall, median, 1-, 5-, 10-year DFS were 3.1 years, 75.5%, 40.4%, and 32.1%,
respectively. After curative intent liver surgery, 209 patients (64.9%) recurred within a median
follow-up of 4.5 years, while 113 (35.1%) patients were alive without disease with a follow-up
time ≥3 years. The site of recurrence was intrahepatic only (n = 111, 65.7%), extrahepatic only
(n = 19, 11.2%), or intra- and extra-hepatic (n = 39, 23.1%). Compared with intrahepatic only
recurrence, extrahepatic only, and combined intra- and extra-hepatic recurrence were
associated with a worse long-term outcome (10-year OS: intrahepatic only, 42.5%, 95%CI,
24.9-59.0 vs extrahepatic only, 0% and combined intra- and extra-hepatic, 21.5%, 95%CI, 5.3-
44.0) (P < 0.001). Most patients were treated with repeat surgery (n = 49, 36.6%), while 34
(23.5%) patients received a somatostatin analogue, 27 (18.6%) systemic cytotoxic chemother-
apy, and 27 (21.4%) patients had intra-arterial therapy. Ten-year OS among patients who
underwent repeat surgery or intra-arterial treatmentswas 60.3% (95%CI, 34.1-78.8) and52.0%
(95%CI, 30.6-69.9), respectively. Patients who received somatostatin analogues (45.9%95%CI,
22.3-66.9) or systemic chemotherapy (0%) had a shorter long-term survival (P = 0.001).
Conclusion: Recurrence after surgery for NELM occurred among half of patients. Repeat liver
resection for recurrence may offer a reasonable 5-year survival benefit.
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1 | INTRODUCTION
Neuroendocrine tumors arise from cells originating from the neuro-
ectoderm that contain secretory granules producing ectopic hor-
mones. The most common gastro-entero-pancreatic neuroendocrine
tumors (GEP-NET) are carcinoid, insulinomas, gastrinomas, somatos-
tatinomas, glucagonomas, and vipomas. GEP-NET can be either
sporadic or part of themultiple neuroendocrine neoplasia type 1 (MEN
type 1) syndrome. Previously regarded as rare, the incidence of GEP-
NET ranges from 2.5 to 4.5 per 100 000 and the incidence is increasingGaya Spolverato and Fabio Bagante equally contributed to this manuscript.
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worldwide.1 The vast majority of patients with GEP-NET are
diagnosed with either locally advanced or metastatic disease. In
fact, while the natural history of many GEP-NET can be indolent, up to
60-90% of patients develop liver metastasis during the course of their
disease.2 The presence of neuroendocrine liver metastases (NELM)
can adversely impact patient quality of life via hormone secretion, as
well as be associated with worse long-term outcomes.3 Specifically,
the 5-year overall survival (OS) of patients with NELM ranges from
13% to 54% versus 75% to 99% for patients with non-metastatic
NET.4–6 As such, treatment of NELM plays a central role in the
management of patients with NET.7
While management strategies for NELM include non-surgical
approaches such as intra-arterial (IAT) or systemic targeted agents,8–14
as well as octreotide and tyrosine kinases inhibitors,11–13 surgery
offers the best potential for cure.6,15,16 Surgical resection of NELMhas
been associatedwith 5-year OS ranging from 61% to 76% and 10-year
survival of 35% to 51%.17,18 Our group had previously reported that
statistical cure following resection of NELM was 44% within 5.1 years
after surgery.19 These data suggest, however, that many patients
experience recurrence. In particular, intrahepatic disease progression
or recurrence has been reported to be as high as 70-90% within
5 years, depending on initial NELM tumor burden.14,18
The preferred management of patients with recurrent NELM
following an initial surgical resection remains controversial. Several
studies have reported on the safety and efficacy of repeat surgery in
the treatment of colorectal liver metastasis, hepatocellular carcinoma,
and intrahepatic cholangiocarcinoma.20–23 Data on repeat surgical
management of recurrent NELM are lacking, however. As such, the
objective of the current study was to define the incidence and pattern
of recurrent NELM following initial surgical resection. In addition, we
sought to characterize the treatment of recurrent NELM and define
treatment-specific long-term outcomes.
2 | MATERIALS AND METHODS
2.1 | Patient demographic and clinical data
Between 1990 and 2014, 322 patients undergoing curative intent liver
surgery for NELM were identified from a multi-institutional database
(Johns Hopkins Hospital, Baltimore, MD; Scientific Institute San
Raffaele, Vita-Salute San Raffaele University, Milan, Italy; Stanford
University, Stanford, CA; University of Virginia, Charlottesville, VA;
Washington University, School ofMedicine, St Louis, MO; Curry Cabral
Hospital, Lisbon,Portugal; EmoryUniversity, Atlanta,GA).Only patients
with histologically confirmed NELM or patients with radiological and
clinical features highly suspicious for NELMwere included in the study
cohort. Patients who underwent curative intent surgery as initial
treatment ofNELMwere identified and included; patientswho received
palliative surgical therapy or a non-surgical treatment (eg, IAT and/or
only somatostatin analogs/tyrosine kinase inhibitors) were excluded.
Patientswhodiedwithin 30daysafter surgery andpatientswithmissing
follow-up informationwere excluded. The Institutional ReviewBoard of
each participating institution approved the study.
Standard patient demographic and clinicopathologic data were
collected including age, gender, race, symptoms, site, andmanagement
of primary tumor, time to development of liver metastasis, number of
NELM and presence of extrahepatic metastasis were collected. Data
regarding treatment details of the primary tumor were also collected
including type of surgery and receipt of adjuvant chemotherapy and
radiotherapy. Data on the initial surgical treatment of NELM, including
intent of treatment, type of liver resection, extent of hepatic resection
and timing between primary resection and diagnosis/treatment of
NELM were recorded.
Date of last follow-up, vital status and recurrence-related
information were collected on all patients. Recurrence was defined
as the presence of a biopsy-proven recurrence ormass on imaging that
had features highly suspicious of tumor recurrence. Data on site and
number of NELM, as well as the disease-free interval (defined as the
time from the date of initial operation to the development of recurrent
disease) was recorded. Recurrences were classified as intrahepatic,
extrahepatic, and both intra- and extra-hepatic. Data on treatment of
recurrent NELM were also collected and categorized as repeat
surgery, somatostatin analogue therapy, systemic cytotoxic chemo-
therapy, or IAT. IAT consisted of transarterial chemoembolization
(TACE), bland transarterial embolization (TAE), drug eluting beads
(DEB), or yttrium-90 (Y-90).
2.2 | Statistical analysis
Continuous and categorical variables were reported as medians with
interquartile ranges (IQR) and as whole numbers and percentages,
respectively. The distributions of categorical variables were compared
using the Fisher’s exact test while continuous variables were
compared using the Mann-Whitney U-test. OS was defined as the
time interval between the date of treatment and the date of death.
Time was censored at the date of last follow-up assessment for all
patients who were alive. Disease-free survival (DFS) was defined as
the time interval between the date of surgery and the date of
recurrence. Time was censored at the date of the last follow-up for
patients who were noted to be free from disease. A P-value <0.05 was
considered to be statistically significant. For statistical analysis, STATA
software (StataCorporation, 2011, MP—Parallel Edition), and R CRAN
software (v. 3.2.2, 2015) with the packages “survival,” “Hmisc,” “rms,”
and “ROCR” were used.
3 | RESULTS
3.1 | Clinicopathological and treatment
characteristics
Among the 322 patients who met inclusion criteria, 209 (64.9%)
patients developed a recurrence with a median follow-up of 4.5 years.
Baseline characteristics of patients who recurred after curative-intent
therapy for NELM are summarized in Supplementary Table S1.Median
patient age was 58 years (IQR 49.0-67.0) and the majority of patients
were male (n = 164, 50.9%). Most primary NET were pancreatic
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TABLE 1 Timing of recurrence (n = 322)
Variable N (%) N (%) N (%) P-value
Timing of recurrence No recurrence Early recurrence Late recurrence
N = 113 N = 152 N = 57
Age, years, median (IQR) 59.3 (48.3-68.2) 58.0 (49.0-66.8) 57.9 (53.0-65.0) 0.84
Gender 0.56
Male 53 (32.3%) 81 (49.4%) 30 (18.3%)
Female 60 (37.9%) 71 (44.9%) 27 (17.2%)
Location of primary NET 0.005
Gastrointestinal 48 (31.6%) 81 (52.6%) 24 (15.8%)
Pancreas 49 (33.8%) 66 (45.5%) 30 (20.7%)
Other 16 (69.6%) 5 (21.7%) 2 (8.7%)
Functional status
Non-functional 26 (16.3%) 98 (61.3%) 36 (22.5%) <0.001
Functional 47 (48.9%) 37 (38.5%) 12 (12.5%)
Grade of differentiation 0.006
Well 65 (48.5%) 47 (35.1%) 22 (16.4%)
Moderate 22 (34.4%) 35 (54.7%) 7 (10.9%)
Poor 11 (22.5%) 28 (57.1%) 10 (20.4%)
Lymph node status <0.001
N0 83 (60.2%) 38 (27.5%) 17 (12.3%)
N1 25 (16.5%) 96 (63.6%) 30 (19.9%)
Synchronous disease 0.015
No 60 (44.1%) 54 (39.7%) 22 (16.2%)
Yes 53 (28.7%) 97 (52.4%) 35 (18.9%)
Treatment before liver surgery <0.001
None 70 (32.4%) 104 (47.7%) 43 (19.9%)
Octreotide 32 (64.0%) 15 (30.0%) 3 (6.0%)
Chemotherapy 4 (19.4%) 16 (58.1%) 5 (22.6%)
Liver involvement <0.001
≥50% 62 (27.6%) 118 (52.4%) 45 (20.0%)
<50% 48 (71.6%) 16 (23.9%) 3 (4.5%)
Location 0.31
Unilobar 25 (21.9%) 64 (56.1%) 25 (21.9%)
Bilobar 50 (31.1%) 85 (51.2%) 31 (18.7%)
Intraoperative tumor ablation 0.005
No 100 (39.7%) 108 (42.9%) 44 (17.5%)
Yes 13 (19.1%) 42 (61.8%) 13 (19.1%)
Extrahepatic disease at diagnosis 0.001
No 111 (38.3%) 132 (45.5%) 47 (16.2%)
Yes 2 (6.3%) 20 (65.5%) 10 (31.3%)
Margin status <0.001
R0 102 (44.8%) 96 (42.4%) 34 (12.9%)
R1 15 (18.9%) 46 (58.2%) 18 (22.9%)
Adjuvant therapy <0.001
None 54 (39.1%) 62 (44.9%) 22 (15.9%)
Octreotide 13 (17.6%) 42 (56.8%) 19 (25.7%)
Chemotherapy 3 (8.3%) 28 (77.8%) 5 (13.9%)
(Continues)
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(n = 145, 45.3%) or gastrointestinal (n = 153, 47.5%) in origin. At the
time of diagnosis, 185 (57.6%) patients had synchronous metastatic
disease. The majority of patients had bilateral hepatic metastases
(n = 166; 59.3%), which often involved more than 50% of the liver
parenchyma (n = 225; 77.1%). Overall, 32 (9.9%) patients had
extrahepatic metastases. The majority of patients (n = 217; 74.3%)
did not receive preoperative treatment prior to the initial surgery; a
subset of patients did receive a somatostatin analog (n = 50; 17.1%) or
cytotoxic chemotherapy (n = 25; 8.6%).
On final pathology, 151 (52.2%) patients had at least one
metastatic lymph node (N1). Margin status was R0 in the majority
of patients (n = 232; 74.6%), while roughly a quarter of patients (n = 79;
25.4%) had an R1 margin. The tumor was either well-differentiated
(n = 134; 54.3%), moderately differentiated (n = 64; 25.9%), or poorly
differentiated (n = 49; 19.8%). Roughly half of patients received
adjuvant therapy with either a somatostatin analog (n = 74, 29.8%) or
systemic cytotoxic chemotherapy (n = 36, 14.5%).
3.2 | Factors associated with recurrence and timing
of recurrence
Overall, median, 1-, 5-, 10-year DFSwere 3.1 years, 75.5%, 40.4%, and
32.1%, respectively. After curative intent liver surgery, 209 patients
(64.9%) recurred, while 113 (35.1%) patients were alive without
disease with a follow-up time ≥3 years.
Patients with a pancreatic or gastrointestinal primary NET had a
higher incidence of recurrence (pancreatic NET: n = 96; 66.2% and
gastrointestinal NET: n = 105; 68.4%) versus patients who had a primary
NET from a non-pancreatic or gastrointestinal origin (other NET: n = 7,
30.4%; Table 1). In addition, patients with a primary pancreatic NET had
higher risk of a late recurrence (n = 30, 20.7%) compared with either
patients who had gastrointestinal NET (n = 24, 15.8%) or a primary NET
from another origin (n = 2, 8.7%) (P < 0.05). Tumor grade was also
associated with the incidence of recurrence (well-differentiated: n = 69,
51.5% vs moderately differentiated: n = 42, 65.6% vs poorly differenti-
ated: n = 38, 77.5%) (P = 0.006). Other factors associatedwith recurrence
included lymph node status (N0: n = 55, 39.8% vs N1: n= 126, 83.5%),
≥50% of liver involvement (<50%: n = 19, 28.4% vs ≥50%: n = 163,
72.4%), and margin status (R0: n = 130, 55.3% vs R1: n =64, 81.1%) (all
P < 0.05).Among the209patientswho recurred, 152 (72.7%)hadanearly
recurrence (≤3 years), whereas 57 (27.3%) experienced a late recurrence
(>3 years). Several clinical and tumor characteristics were associatedwith
the timing of recurrence (Table 1). For example, patients who had an R0
versus R1 margin had a comparable incidence of early recurrence (R0,
n = 89, 42.4%; R1, n = 46, 58.2%), while R1 patients had almost a twofold
increase incidence of late recurrence (R0, n = 27, 12.9%; R1, n = 18,
22.9%) (P < 0.001). The incidence of both early (<3 years) and late (≥3
years) recurrencewasnearlydoubleamongpatientswithanon-functional
NET (early: n = 98, 61.3%; late: n = 36, 22.5%) compared with patients
who had a functional NET (early: n = 37, 38.5%; late: n = 12, 12.5%)
(P < 0.001). In addition, when stratified by extent of liver disease, the
incidenceof recurrencewasdouble in theearly timeperiod (<50%,n = 16,
23.9% vs ≥50%, n = 118, 52.4%) and increased to almost fourfold in the
late time period (<50%, n = 3, 4.5% vs. ≥50%, n = 45, 20.0%) (P < 0.001).
3.3 | Site of recurrence
Data were available on the specific site of recurrence for 169 out of
the 209 patients who had a recurrence. Among these 169 patients, the
site of recurrence was intrahepatic only (n = 111, 65.7%), extrahepatic
only (n = 19, 11.2%), or intra- and extra-hepatic (n = 39, 23.1%)
(Table 2).
Several factors were associated with the site of recurrence (Fig. 1
and Table 2). Specifically, patients who had an R1 resection weremore
likely to experience an intrahepatic only recurrence (n = 36, 50.8%)
compared with patients who had an R0 resection (n = 66, 32.9%)
(P = 0.001). In contrast, while patients with well- (n = 39, 31.9%),
moderately- (n = 26, 45.6%), or poorly differentiated (n = 18, 40.0%)
tumors had a similar incidence of intrahepatic recurrence, the
incidence of extrahepatic only and combined intra- and extra-hepatic
recurrence were markedly higher among patients with a poorly
differentiated tumor (extrahepatic only: well, n = 4, 3.3% vs moderate,
n = 1, 1.8%; vs poorly, n = 3, 6.7%; combined intra- and extra-hepatic
recurrence: well, n = 14, 11.5% vs moderate, n = 8, 14.0% vs poorly,
n = 13, 28.9%) (both P < 0.05). Extrahepatic recurrence was also much
more common among patientswith pancreatic (n = 11, 9.2%) and other
non-GI NET (n = 2, 9.1%) compared with gastrointestinal NET (n = 6,
4.4%) (P = 0.005). Perhaps not surprisingly, patients who presented
with extrahepatic disease at initial diagnosis were more likely to recur
with either extrahepatic disease only or combined intra- and extra-
hepatic disease (combined intra- and extra-hepatic recurrence:
extrahepatic disease at initial diagnosis, n = 8, 33.3% vs no-extrahe-
patic disease at initial diagnosis, n = 31, 12.0%; extrahepatic only:
extrahepatic disease at initial diagnosis, n = 7, 29.2% vs no-extrahe-
patic disease at initial diagnosis, n = 12, 4.7%) (P < 0.001).
Of note, site of recurrencewas associatedwith time of recurrence.
Specifically, most early recurrences within the first 3 years after
surgery were either intrahepatic only (n = 88, 79.3%) or combined
intra- and extra-hepatic recurrences (n = 31, 79.5%), while late
recurrences after 3 years were more often extrahepatic only (n = 9,
TABLE 1 (Continued)
Variable N (%) N (%) N (%) P-value
Site of recurrence 0.036
Intrahepatic only — 88 (79.3%) 23 (20.7%)
Intra- and extrahepatic — 31 (79.5%) 8 (20.5%)
Extrahepatic only — 10 (52.6%) 9 (47.4%)
Overall survival, 10-year (95%CI) — 41.8% (29.2-53.8) 65.2% (47.3-78.3) <0.001
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TABLE 2 Site of recurrence (n = 282)
Variable N (%) N (%) N (%) N (%) P-value
Type of Recurrence No recurrence Intrahepatic Intra + extrahepatic Extrahepatic
N = 113 n = 111 n = 39 n = 19
Age, years, median (IQR) 59.3 (48.3-68.2) 58 (49.0-66.0) 58.0 (45.5-69.5) 56.0 (50.0-63.4) 0.89
Gender 0.24
Male 53 (36.6%) 59 (40.7%) 25 (17.2%) 8 (5.5%)
Female 60 (43.8%) 52 (37.9%) 14 (10.2%) 11 (8.1%)
Location of primary NET 0.005
Gastrointestinal 48 (34.8%) 67 (47.8%) 18 (13.0%) 6 (4.4%)
Pancreas 49 (40.8%) 45 (36.7%) 16 (13.3%) 11 (9.2%)
Other 16 (72.7%) 1 (4.6%) 3 (13.6%) 2 (9.1%)
Functional status <0.001
Non-functional 26 (19.4%) 79 (58.9%) 21 (15.7%) 8 (5.9%)
Functional 47 (54.7%) 23 (26.7%) 9 (10.5%) 7 (8.1%)
Grade of differentiation
Well 65 (53.3%) 39 (31.9%) 14 (11.5%) 4 (3.3%)
Moderate 22 (38.6%) 26 (45.6%) 8 (14.0%) 1 (1.8%)
Poor 11 (24.4%) 18 (40.0%) 13 (28.9%) 3 (6.7%) 0.009
Lymph node status <0.001
N0 83 (65.4%) 28 (22.1%) 13 (9.5%) 4 (3.2%)
N1 25 (19.1%) 74 (56.5%) 23 (17.6%) 9 (6.9%)
Synchronous disease 0.015
No 60 (47.2%) 43 (33.9%) 12 (9.5%) 12 (9.5%)
Yes 53 (34.2%) 68 (43.9%) 27 (17.4%) 7 (4.5%)
Treatment before liver surgery <0.001
None 70 (37.0%) 79 (41.8%) 29 (15.3%) 11 (5.8%)
Octreotide 32 (71.1%) 9 (20.0%) 3 (6.7%) 1 (2.2%)
Chemotherapy 6 (23.1%) 11 (46.2%) 3 (11.5%) 5 (19.2%)
Liver involvement <0.001
≥50% 62 (31.9%) 88 (45.4%) 28 (14.4%) 16 (8.3%)
<50% 48 (73.8%) 10 (15.4%) 7 (10.8%) 0
Location 0.14
Unilobar 25 (26.0%) 52 (54.2%) 13 (13.5%) 6 (6.3%)
Bilobar 50 (34.7%) 56 (38.9%) 25 (17.4%) 13 (9.0%)
Intraoperative tumor ablation 0.011
No 101 (45.3%) 77 (34.8%) 30 (13.6%) 14 (6.3%)
Yes 13 (22.0%) 32 (54.2%) 9 (15.3%) 5 (8.5%)
Extrahepatic disease at diagnosis <0.001
No 111 (43.0%) 104 (40.3%) 31 (12.0%) 12 (4.7%)
Yes 2 (8.3%) 7 (29.2%) 8 (33.3%) 7 (29.2%)
Margin status 0.001
R0 97 (49.2%) 66 (32.9%) 24 (12.0%) 12 (5.8%)
R1 17 (22.4%) 36 (50.8%) 12 (16.4%) 8 (10.5%)
Adjuvant therapy
None 54 (43.2%) 43 (34.4%) 21 (16.8%) 7 (5.6%)
Octreotide 13 (21.7%) 34 (56.7%) 8 (13.3%) 5 (8.3%)
Chemotherapy 3 (9.4%) 19 (59.4%) 6 (18.8%) 4 (12.5%)
Overall survival, 10-year (95%CI) — 42.5% (24.9-59.0) 21.5% (5.3-44.9) 0% <0.001
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47.4%) (P = 0.03). Timing of recurrence was also associated with
prognosis, as patients who experienced an early recurrence had a
worse prognosis (10-year OS: early recurrence, 41.8%, 95%CI, 29.2-
53.8 vs late recurrence, 65.2%, 95%CI, 47.3-78.3) (P = 0.001).
Compared with intrahepatic only recurrence, extrahepatic only and
combined intra- and extra-hepatic recurrence were associated with a
worse long-term outcome (10-year OS: intrahepatic only, 42.5%, 95%
CI, 24.9-59.0 vs extrahepatic only, 0% and combined intra- and extra-
hepatic, 21.5%, 95%CI, 5.3-44.0) (Fig. 2; P < 0.001).
3.4 | Treatment of recurrence and long-term
outcomes
Among the 137 patients who had information available on the
treatment of recurrence, most patients were treated with repeat
surgery (n = 49, 36.6%), while 34 (23.5%) patients received a
somatostatin analogue, 27 (18.6%) systemic cytotoxic chemotherapy,
and 27 (21.4%) patients had IAT. Patients with intrahepatic only
recurrence were treated more often with repeat surgery (n = 39,
43.8%), while patients with intra- and extra-hepatic recurrence were
more frequently treated with somatostatin analogues (n = 14, 43.8%)
and chemotherapy (n = 12, 37.5%; P < 0.001). Of note, late recurrence
was treated more often with repeat surgical resection (n = 9, 40.9%) or
with somatostatin analogues (n = 9, 40.9%) than with systemic
chemotherapy (n = 3, 16.6%) and IAT (n = 1, 4.6%). In comparison,
systemic chemotherapy (n = 24, 23.1%) and IAT (n = 24, 23.1%) were
employed with similar frequencies as somatostatin analogues (n = 25,
FIGURE 1 Histograms representing the incidence of (A) margin status, (B) grade of tumor differentiation, (C) location of primary NET, (D)
extrahepatic disease at diagnosis, and (E) timing of recurrence among the different types of recurrence
FIGURE 2 Kaplan-Maier overall survival curves stratified by site
of recurrence
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24.0%) and repeat surgical resection (n = 31, 29.8%) for the treatment
of early recurrence (Table 3; P = 0.08).
Following treatment of recurrent disease, 10-year OS among
patients who underwent repeat surgery and intra-arterial treatments
was 60.3% (95%CI, 34.1-78.8) and 52.0% (95%CI, 30.6-69.9),
respectively. In contrast, patientswho received somatostatin analogue
(45.9% 95%CI, 22.3-66.9) or systemic chemotherapy (0%) had a
shorter long-term survival (Fig. 3; P = 0.001).
4 | DISCUSSION
While NET are derived from a wide variety of primary tumor sites,
secondary metastatic disease is a common feature regardless of where
the tumor originated. The presence of NELM is one of the most
important predictors of survival, while also frequently impacting the
quality of life of patients with NET.6 Despite several nonsurgical
therapies, surgery often is the cornerstone of the treatment of patients
with NELM. In fact, several studies have evaluated and compared
different treatment approaches for patients with NELM.24–27 Most
previous studies did not, however, focus on the treatment of recurrent
NELM. The current study is important because, using a large,
international, multi-institutional cohort of patients, we characterized
the overall pattern of NELM recurrence following curative intent
surgery and defined the incidence of recurrence to be 64.9% within a
median follow up of 4.5 years. The majority of patients (72.7%)
developed recurrence within 3 years after surgery. Several clinico-
pathological factors, such as functional status, presence of metastatic
lymphnodes, gradeof tumordifferentiation, and liver involvementwere
associated with a higher likelihood of recurrence. Indeed, these
clinicopathological characteristics were particularly associated with
the riskof early versus late recurrence (Table1). In turn, early recurrence
was associated with a worse prognosis compared with late recurrence
(10-year OS: early recurrence, 41.8%, 95%CI, 29.2-53.8 vs late
recurrence, 65.2%, 95%CI, 47.3-78.3) (P = 0.001). These findings
suggest that specific clinicopathological characteristics are more likely
to impact long-termoutcomebybeingassociatedwith early recurrence.
Themost common pattern of recurrencewas intrahepatic (65.7%),
while fewer patients had an extrahepatic component of recurrent
disease (extrahepatic only, 11.2%; combined intra- and extrahepatic,
23.1%;). Patients with intrahepatic recurrence were more likely to
have undergone an R1 resection and more often had poorly
differentiated tumors. Patients with liver involvement ≥50% at the
time of surgery were also more likely to have intrahepatic recurrence,
while patients with <50% of liver involvement had a lower risk of any
recurrence. Of note, patients with NELM from a pancreatic NET
primary recurredmore frequently at extrahepatic sites than in the liver
(Table 2). Perhaps not surprisingly, pattern of recurrence seemed to
impact long-term outcomes (Fig. 2). Specifically, patients who had an
extrahepatic component of recurrent disease had a worse prognosis
compared with patients who had only intrahepatic recurrence (10-
year OS: intrahepatic only, 42.5%; extrahepatic only, 0%; combined
intra- and extra-hepatic, 21.5%) (P < 0.001).
While repeat hepatectomy has been advocated as the treatment
of choice for recurrent hepatocellular carcinoma22 and colorectal liver
metastasis,20 data on different management options for patients with
recurrent NELM are lacking. In the present study, surgery was the
most common treatment choice of recurrent NELM (36.6%), while one
fifth of patients received IAT (21.4%), one fourth were treated with
somatostatin analogues (23.5%), and the remaining patients were
received chemotherapy (18.6%). Surgery was the treatment of choice
of patients with intrahepatic recurrence (43.8%), while patients with
intra- and extra-hepatic recurrence more frequently received somato-
statin analogues (43.8%) and those patients with extra-hepatic
recurrence (75%) were more likely to receive chemotherapy. Patients
who had early recurrence were equally treated with any type of
surgical and non-surgical approach, while patients with late recurrence
more frequently underwent surgery or somatostatin analogs. Repeat
liver surgery has been demonstrated to be increasingly safe and
effective for a wide variety of tumors.28 In particular, the combination
of surgical resection with ablation may provide a chance for tumor
eradication among patients with a large tumor burden or with
recurrent NELM.29,30 In one study by Mayo et al that reported on 339
patientswho underwent surgical management for NELM, the extent of
TABLE 3 Treatment of recurrence (n = 137)
Variable N (%) N (%) N (%) N (%)
P-
value
Treatment of recurrence S o m a t o s t a t i n
analogous
Chemotherapy IAT Surgery
N = 34 n = 27 n = 27 n = 49
Site of recurrence <0.001
Intrahepatic only 19 (21.4%) 12 (13.5%) 19 (21.4%) 39 (43.8%)
Intra- and Extrahepatic 14 (43.8%) 12 (37.5%) 5 (15.6%) 1 (3.1%)
Extrahepatic only 1 (25.0%) 3 (75.0%) — —
Time of recurrence 0.077
Early 25 (24.0%) 24 (23.1%) 24 (23.1%) 31 (29.8%)
Late 9 (40.9%) 3 (16.6%) 1 (4.6%) 9 (40.9%)
Overall survival after treatment of recurrence, 10-year
(95%CI)
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hepatic resection among patients who underwent a repeat operation
progressively diminished while ablation was used with increased
frequency.17 Collectively, data from previous reports as well as the
current study, suggest that surgery, including with resection alone or
with resection plus ablation should be considered for patients with
recurrent disease—especially those with limited disease. For patients
with more extensive disease, IAT may be a good option as this
therapeutic approach was associated with a good long-term 10-year
OS of over 50%.
This study has several limitations that should be considered when
interpreting the results. First, the retrospective design of the study
likely resulted in some confounding and selection/detection biases. In
addition, because data were collected from multiple international
centers, there was possible heterogeneity with the selection criteria
and treatment approach for recurrent NELM disease. The inclusion of
data from multiple centers does, however, increase the generalization
of the findings. Finally, despite a large overall sample size, the relatively
low number of patients with information on recurrence limited some
of the subset analyses.
In conclusion, recurrence after curative intent surgery for NELM
was common, occurring in three fourth of patients. Intrahepatic
recurrence was the most common pattern of recurrence, although
extrahepatic recurrence was also frequent. Pattern of recurrence
was associated with specific clinical factors and impacted overall
survival. When patients recur with NELM following initial surgical
resection, therapy needs to be tailored with repeat liver resection
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